DBV Technologies S.A. (0QAJ.IL)

3.5700 -0.0770 (-2.11%) At close: 06:04PM BST

DBV Technologies S.A.

177-181 Avenue Pierre Brossolette
Montrouge 92120
France
33 1 55 42 78 78
https://www.dbv-technologies.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 88

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Daniel Tassé	CEO & Director	1.14M	N/A	1960
Mr. Sébastien Robitaille	Chief Financial Officer	339.08k	N/A	1970
Dr. Pharis Mohideen	Chief Medical Officer	690.3k	N/A	1965
Mr. Pascal Wotling	Chief Technical Operations Officer & Chief Quality Officer	N/A	N/A	N/A
Anne Pollak	Head of Investor Relations	N/A	N/A	N/A
Ms. Michele F. Robertson	Chief Legal Officer	N/A	N/A	N/A
Joseph Becker	VP of Global Corp. Communications	N/A	N/A	N/A
Ms. Caroline Daniere	Chief HR Officer & Chief of Staff	N/A	N/A	1975
Dr. Wence Agbotounou	Chief Clinical Trial Officer & Sr. VP	N/A	N/A	N/A
Ms. Lucie Mondoulet	Sr. VP & Deputy CSO	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Corporate governance

DBV Technologies S.A.’s ISS governance QualityScore as of 1 July 2022 is 8. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.